Sebastián Rivera-Orellana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sebastián Rivera-Orellana has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Andrés López-Cortés
Cancer Research Group (CRG), Faculty of Medicine, Universidad de las Américas
2 shared publications - Andrés Herrera-Yela
Emerging and Neglected Diseases Group, Health Sciences Faculty, Universidad Internacional SEK (UISEK), Quito 170102, Ecuador
1 shared publication - Eduardo Tejera
Bio-Cheminformatics Research Group, Universidad de Las Américas, Quito 170504, Ecuador
1 shared publication - Jaime David Acosta-España
Health Sciences Faculty, Universidad Internacional SEK (UISEK), Quito 170120, Ecuador
1 shared publication - Jorge Espinosa-Espinosa
Translational Genomics Group, University Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, 46100 Burjasot, Spain
1 shared publication - José Rubén Ramírez-Iglesias
Emerging and Neglected Diseases Group, Health Sciences Faculty, Universidad Internacional SEK (UISEK), Quito 170120, Ecuador
1 shared publication
Latest Publications
- Open Access
NeoPhAR: Next-generation Phage Therapy for Antimicrobial Resistance
Growing antimicrobial resistance (AMR) infections are among the top contemporary concerns in public healthcare systems which can place considerable burdens on healthcare systems. Phage therapy has long been considered a viable option to help combat AMR infections, including on broad geographic scales. One bottleneck in the application of phage therapy is the accurate matching of host-specific phages to bacterial strains, which is traditionally done using molecular techniques. Here we present an open-access deep learning-based model that shows incredible potential to accurately predict phages for therapeutic use. Our goal is to attenuate the matching process so that specific phages, or a cocktail of phages can be prepared for patients with a high probability of therapeutic success, helping to democratize phage therapy treatments even in low to middle-income countries where genomic resources can be limited, costly, or time prohibitive. We feel this is an important first step towards incorporating and applying bioinformatic practices in promising fields such as phage therapy.
Open AccessNeoPhAR: Next-generation Phage Therapy for Antimicrobial Resistance
Growing antimicrobial resistance (AMR) infections are among the top contemporary concerns in public healthcare systems which can place considerable burdens on healthcare systems. Phage therapy has long been considered a viable option to help combat AMR infections, including on broad geographic scales. One bottleneck in the application of phage therapy is the accurate matching of host-specific phages to bacterial strains, which is traditionally done using molecular techniques. Here we present an open-access deep learning-based model that shows incredible potential to accurately predict phages for therapeutic use. Our goal is to attenuate the matching process so that specific phages, or a cocktail of phages can be prepared for patients with a high probability of therapeutic success, helping to democratize phage therapy treatments even in low to middle-income countries where genomic resources can be limited, costly, or time prohibitive. We feel this is an important first step towards incorporating and applying bioinformatic practices in promising fields such as phage therapy.
- Open Access
Mpox Vaccine Design Through Immunoinformatics and Computational Epitope Prediction
The Mpox virus (Monkeypox virus) poses significant public health risks due to its potential for severe outbreaks in humans. This study presents an innovative vaccine design using bioinformatics to identify epitopes that activate helper T cells (HTLs) via the human leukocyte antigen class II (HLA-II) complex. Starting with 50,040 vaccine candidates, 14 epitopes with the highest HLA-II affinity were selected based on antigenicity, allergenicity, toxicity, stability, and homology. These epitopes were integrated into a multi-epitope vaccine with spacers and adjuvants to enhance the immune response. A 3D model was developed, confirming structural stability and optimal epitope exposure through molecular dynamics simulations. The results indicate that the vaccine can induce robust immune responses, suggesting its potential effectiveness against the Mpox virus. Additionally, population coverage analysis supports its promise as a significant tool for controlling Mpox epidemics and advancing global public health initiatives.
Open AccessMpox Vaccine Design Through Immunoinformatics and Computational Epitope Prediction
The Mpox virus (Monkeypox virus) poses significant public health risks due to its potential for severe outbreaks in humans. This study presents an innovative vaccine design using bioinformatics to identify epitopes that activate helper T cells (HTLs) via the human leukocyte antigen class II (HLA-II) complex. Starting with 50,040 vaccine candidates, 14 epitopes with the highest HLA-II affinity were selected based on antigenicity, allergenicity, toxicity, stability, and homology. These epitopes were integrated into a multi-epitope vaccine with spacers and adjuvants to enhance the immune response. A 3D model was developed, confirming structural stability and optimal epitope exposure through molecular dynamics simulations. The results indicate that the vaccine can induce robust immune responses, suggesting its potential effectiveness against the Mpox virus. Additionally, population coverage analysis supports its promise as a significant tool for controlling Mpox epidemics and advancing global public health initiatives.